Paradigm Asset Management Co. LLC Increases Stake in Haleon PLC Sponsored ADR $HLN

Paradigm Asset Management Co. LLC lifted its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 7,466.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 357,120 shares of the company’s stock after buying an additional 352,400 shares during the period. Paradigm Asset Management Co. LLC’s holdings in Haleon were worth $1,800,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Atlantic Union Bankshares Corp boosted its position in shares of Haleon by 293.7% during the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after purchasing an additional 2,758 shares in the last quarter. Stance Capital LLC bought a new stake in shares of Haleon during the third quarter valued at approximately $34,000. Geneos Wealth Management Inc. grew its position in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after buying an additional 1,203 shares during the period. Assetmark Inc. grew its position in shares of Haleon by 26.6% in the 4th quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after buying an additional 1,252 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Haleon by 428.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after buying an additional 5,124 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on HLN shares. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Haleon presently has a consensus rating of “Moderate Buy” and an average price target of $13.40.

Haleon Price Performance

HLN stock opened at $9.11 on Wednesday. The stock has a 50-day moving average price of $9.84 and a two-hundred day moving average price of $9.97. The stock has a market cap of $40.47 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 2.04 and a beta of 0.15. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42.

Haleon (NYSE:HLN) last released its earnings results on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The firm had revenue of $3.65 billion for the quarter. Equities analysts forecast that Haleon PLC Sponsored ADR will post 0.56 EPS for the current fiscal year.

Haleon Dividend Announcement

The company also recently announced a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a dividend of $0.1307 per share. This represents a yield of 266.0%. The ex-dividend date is Friday, April 10th. Haleon’s dividend payout ratio is 64.10%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.